收稿日期: 2022-06-01
录用日期: 2022-12-30
网络出版日期: 2023-01-28
基金资助
国家自然科学基金(81900680)
Role of methyltransferase like 3 regulating pri-miR-21 methylation in renal fibrosis of diabetes nephropathy
Received date: 2022-06-01
Accepted date: 2022-12-30
Online published: 2023-01-28
Supported by
National Natural Science Foundation of China(81900680)
目的·探讨甲基转移酶3(methyltransferase like 3,METTL3)调控pri-miR-21的N6-甲基腺苷(N6-methyladenosine,m6A)甲基化修饰在糖尿病肾病(diabetic nephropathy,DN)小鼠肾脏纤维化发病机制中的作用。方法·采用8周龄雄性db/db小鼠作为DN模型小鼠,db/m小鼠作为对照,同时按照是否经尾静脉注射S-腺苷高半胱氨酸水解酶抑制剂3-脱氮腺苷(3-deazaadenosine,DAA),共随机分为4组(5只/组),分别为db/m组、db/db组、db/m+DAA组和db/db+DAA组;8周龄开始注射DAA,注射1次/5 d,共注射8次。DAA干预结束后继续饲养小鼠至19周龄,收取各组小鼠血、尿、肾脏组织标本。检测血糖、血肌酐、尿白蛋白肌酐比(albumin-to-creatinine ratio,ACR),肾脏行苏木精-伊红(H-E)染色、Masson染色及天狼星红染色观察病理变化;试剂盒检测肾脏总RNA中m6A的甲基化水平;Western blotting检测肾脏METTL3及纤维化相关蛋白表达;实时定量PCR检测肾脏总pri-miR-21和成熟miR-21;使用免疫磁珠富集肾脏组织中m6A甲基化RNA,并通过PCR检测其中m6A甲基化的pri-miR-21。结果·相较于db/m组,db/db组小鼠血糖,血肌酐,ACR,肾脏METTL3、m6A甲基化修饰水平、纤维化相关蛋白、总pri-miR-21、m6A甲基化pri-miR-21和成熟miR-21表达水平均显著增加(均P<0.05),小鼠肾脏系膜基质增多、肾小球基底膜增厚、胶原纤维累积显著增加。相较于db/db组,db/db+DAA组血糖,血肌酐,ACR,肾脏m6A甲基化修饰水平、纤维化相关蛋白、m6A甲基化pri-miR-21和成熟miR-21表达水平均显著下降(均P<0.05),总pri-miR-21表达水平显著升高(P=0.000),METTL3蛋白表达水平未见显著变化,小鼠肾脏损伤及纤维化程度显著减轻。结论·pri-miR-21的m6A甲基化修饰促进miR-21成熟,进而促进DN小鼠肾脏纤维化的发生发展;抑制METTL3可通过调控pri-miR-21的m6A甲基化修饰抑制DN小鼠肾脏纤维化。
吴佳晋 , 钟晨 , 李大伟 , 陈若洋 , 瞿俊文 , 张明 . 甲基转移酶3调控pri-miR-21甲基化修饰在糖尿病肾病肾脏纤维化中的作用[J]. 上海交通大学学报(医学版), 2023 , 43(1) : 1 -7 . DOI: 10.3969/j.issn.1674-8115.2023.01.001
Objective ·To investigate the role of methyltransferase like 3 (METTL3) acting on N6-methyladenosine (m6A) and regulating pri-miR-21 methylation in the renal fibrosis of diabetic nephropathy (DN). Methods ·Eight-week-old male db/db mice were used as DN models, and db/m mice were used as controls. The mice were randomly divided into 4 groups according to whether they received the treatment of 3-deazaadenosine (DAA) by tail vein injection or not (5 mice/group): db/m group, db/db group, db/m+DAA group and db/db+DAA group. From the age of 8 weeks, DAA was injected once per 5 d for a total of 8 times. After the DAA intervention, the mice were kept until they were 19 weeks old. The blood, the urine and the kidney tissue samples of the mice were collected, and blood glucose (BG), serum creatinine (Scr), and urinary albumin-to-creatinine ratio (ACR) were detected. The kidneys were stained with hematoxylin-eosin (H-E), Masson and sirius red to observe the pathological changes. The methylation level of m6A in total RNAs of the kidney was detected with the kit. The expression levels of METTL3 and fibrosis-related proteins in the kidney were detected by Western blotting. The overall pri-miR-21 and the mature miR-21 were detected by real-time quantitative PCR. After enrichment of the m6A-methylated RNAs in the kidney by immunomagnetic beads, the methylated pri-miR-21 at m6A was detected by PCR. Results ·Compared with the db/m group, the levels of BG, Scr, and ACR, and METTL3, m6A methylation level, fibrosis-related proteins, overall pri-miR-21, m6A-methylated pri-miR-21 and mature miR-21 in the kidney in the db/db group significantly increased (P<0.05). Furthermore, the mesangial matrix in the kidney increased, glomerular basement membrane thickened, and the accumulation of collagen fibers increased significantly in the db/db group. Compared with the db/db group, the levels of BG, Scr, and ACR, and m6A methylation level, fibrosis-related proteins, m6A-methylated pri-miR-21 and mature miR-21 in the kidney in the db/db+DAA group decreased significantly (P<0.05) and the degree of renal injury and fibrosis was significantly reduced, but the expression level of overall pri-miR-21 significantly increased (P=0.000). The expression level of METTL3 protein did not change significantly. Conclusion ·The m6A methylation modification of pri-miR-21 promotes the maturation of miR-21, thereby promoting the occurrence and development of renal fibrosis in DN mice; inhibition of METTL3 can inhibit renal fibrosis in DN mice by regulating m6A methylation of pri-miR-21.
1 | CHANG Y E, MORADI H, KALANTAR-ZADEH K. Emerging paradigms of treating diabetic nephropathy[J]. Lancet Diabetes Endocrinol, 2018, 6(12): 912-913. |
2 | CHERNEY D Z I, ODUTAYO A, VERMA S. A big win for diabetic kidney disease: CREDENCE[J]. Cell Metab, 2019, 29(5): 1024-1027. |
3 | DE BOER I H. A new chapter for diabetic kidney disease[J]. N Engl J Med, 2017, 377(9): 885-887. |
4 | JARDINE M J, MAHAFFEY K W, PERKOVIC V. Canagliflozin and renal outcomes in diabetic nephropathy. Reply[J]. N Engl J Med, 2019, 381(11): 1089-1090. |
5 | CHAU B N, XIN C Y, HARTNER J, et al. MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways[J]. Sci Transl Med, 2012, 4(121): 121ra18. |
6 | WANG J Y, GAO Y B, ZHANG N, et al. Tongxinluo ameliorates renal structure and function by regulating miR-21-induced epithelial-to-mesenchymal transition in diabetic nephropathy[J]. Am J Physiol Renal Physiol, 2014, 306(5): F486-F495. |
7 | DEY N, DAS F, MARIAPPAN M M, et al. MicroRNA-21 orchestrates high glucose-induced signals to TOR complex 1, resulting in renal cell pathology in diabetes[J]. J Biol Chem, 2011, 286(29): 25586-25603. |
8 | YANG C, HU Y Y, ZHOU B, et al. The role of m6A modification in physiology and disease[J]. Cell Death Dis, 2020, 11(11): 960. |
9 | MATHIYALAGAN P, ADAMIAK M, MAYOURIAN J, et al. FTO-dependent N6-methyladenosine regulates cardiac function during remodeling and repair[J]. Circulation, 2019, 139(4): 518-532. |
10 | LIU E P, LV L, ZHAN Y H, et al. METTL3/N6-methyladenosine/miR-21-5p promotes obstructive renal fibrosis by regulating inflammation through SPRY1/ERK/NF-κB pathway activation[J]. J Cell Mol Med, 2021, 25(16): 7660-7674. |
11 | CHEN J, ZHANG M J, ZHANG X, et al. EZH2 inhibitor DZNep modulates microglial activation and protects against ischaemic brain injury after experimental stroke[J]. Eur J Pharmacol, 2019, 857: 172452. |
12 | OVECHKIN A V, TYAGI N, SEN U, et al. 3-Deazaadenosine mitigates arterial remodeling and hypertension in hyperhomocysteinemic mice[J]. Am J Physiol Lung Cell Mol Physiol, 2006, 291(5): L905-L911. |
13 | MEYER K D, SALETORE Y, ZUMBO P, et al. Comprehensive analysis of mRNA methylation reveals enrichment in 3' UTRs and near stop codons[J]. Cell, 2012, 149(7): 1635-1646. |
14 | NIU Y M, ZHAO X, WU Y S, et al. N6-methyl-adenosine (m6A) in RNA: an old modification with a novel epigenetic function[J]. Genom Proteom Bioinform, 2013, 11(1): 8-17. |
15 | LIU J Z, YUE Y N, HAN D L, et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation[J]. Nat Chem Biol, 2014, 10(2): 93-95. |
16 | MAGHBOOLI Z, LARIJANI B, EMAMGHOLIPOUR S, et al. Aberrant DNA methylation patterns in diabetic nephropathy[J]. J Diabetes Metab Disord, 2014, 13(1): 69. |
17 | MARUMO T, YAGI S, KAWARAZAKI W, et al. Diabetes induces aberrant DNA methylation in the proximal tubules of the kidney[J]. J Am Soc Nephrol, 2015, 26(10): 2388-2397. |
18 | JIANG L, LIU X Q, HU X R, et al. METTL3-mediated m6A modification of TIMP2 mRNA promotes podocyte injury in diabetic nephropathy[J]. Mol Ther, 2022, 30(4): 1721-1740. |
19 | LI Q H, ZHU L Q, YAN Y M, et al. S-adenosyl homocysteine hydrolase (SAHH) accelerates flagellar regeneration in Dunaliella salina[J]. Curr Microbiol, 2013, 67(2): 249-254. |
20 | ZACCARA S, RIES R J, JAFFREY S R. Reading, writing and erasing mRNA methylation[J]. Nat Rev Mol Cell Biol, 2019, 20(10): 608-624. |
21 | DE JESUS D F, ZHANG Z J, KAHRAMAN S, et al. m6A mRNA methylation regulates human β-cell biology in physiological states and in type 2 diabetes[J]. Nat Metab, 2019, 1(8): 765-774. |
22 | XIE W, MA L L, XU Y Q, et al. METTL3 inhibits hepatic insulin sensitivity via N6-methyladenosine modification of Fasn mRNA and promoting fatty acid metabolism[J]. Biochem Biophys Res Commun, 2019, 518(1): 120-126. |
23 | 张丹亭. S-腺苷高半胱氨酸水解酶抑制剂在肝脏葡萄糖糖代谢中的作用[D]. 长春: 东北师范大学, 2019. |
23 | ZHANG D T. 3-Deazaadenosine, mechanism of action in liver glucose metabolism[D]. Changchun: Northeast Normal University, 2019. |
24 | ZHONG X, CHUNG A C K, CHEN H Y, et al. miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes[J]. Diabetologia, 2013, 56(3): 663-674. |
25 | WANG J Y, GAO Y B, ZHANG N, et al. miR-21 overexpression enhances TGF-β1-induced epithelial-to-mesenchymal transition by target smad7 and aggravates renal damage in diabetic nephropathy[J]. Mol Cell Endocrinol, 2014, 392(1-2): 163-172. |
26 | SEKAR D, VENUGOPAL B, SEKAR P, et al. Role of microRNA 21 in diabetes and associated/related diseases[J]. Gene, 2016, 582(1): 14-18. |
27 | DIAO L T, XIE S J, LEI H, et al. METTL3 regulates skeletal muscle specific miRNAs at both transcriptional and post-transcriptional levels[J]. Biochem Biophys Res Commun, 2021, 552: 52-58. |
28 | MICHLEWSKI G, CáCERES J F. Post-transcriptional control of miRNA biogenesis[J]. RNA, 2019, 25(1): 1-16. |
/
〈 |
|
〉 |